The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance.
Highly differentiated epithelial cells of the visceral layer of BOWMAN CAPSULE of the KIDNEY. They are composed of a cell body with major CELL SURFACE EXTENSIONS and secondary fingerlike extensions called pedicels. They enwrap the KIDNEY GLOMERULUS capillaries with their cell surface extensions forming a filtration structure. The pedicels of neighboring podocytes interdigitate with each other leaving between them filtration slits that are bridged by an extracellular structure impermeable to large macromolecules called the slit diaphragm, and provide the last barrier to protein loss in the KIDNEY.
A cluster of convoluted capillaries beginning at each nephric tubule in the kidney and held together by connective tissue.
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
Pathological processes of the KIDNEY or its component tissues.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
A ZINC-dependent membrane-bound aminopeptidase that catalyzes the N-terminal peptide cleavage of GLUTAMATE (and to a lesser extent ASPARTATE). The enzyme appears to play a role in the catabolic pathway of the RENIN-ANGIOTENSIN SYSTEM.
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
Laboratory tests used to evaluate how well the kidneys are working through examination of blood and urine.
A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
A specialized barrier in the kidney, consisting of the fenestrated CAPILLARY ENDOTHELIUM; GLOMERULAR BASEMENT MEMBRANE; and glomerular epithelium (PODOCYTES). The barrier prevents the filtration of PLASMA PROTEINS.
Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY.
Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN.
Water-soluble proteins found in egg whites, blood, lymph, and other tissues and fluids. They coagulate upon heating.
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time.
An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
Individual members of North American ethnic groups with ancient historic ancestral origins in Asia.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.
A non-fibrillar collagen found in the structure of BASEMENT MEMBRANE. Collagen type IV molecules assemble to form a sheet-like network which is involved in maintaining the structural integrity of basement membranes. The predominant form of the protein is comprised of two alpha1(IV) subunits and one alpha2(IV) subunit, however, at least six different alpha subunits can be incorporated into the heterotrimer.
Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.
VASCULAR DISEASES that are associated with DIABETES MELLITUS.
Compounds based on fumaric acid.
An extracellular cystatin subtype that is abundantly expressed in bodily fluids. It may play a role in the inhibition of interstitial CYSTEINE PROTEASES.
Conditions or pathological processes associated with the disease of diabetes mellitus. Due to the impaired control of BLOOD GLUCOSE level in diabetic patients, pathological processes develop in numerous tissues and organs including the EYE, the KIDNEY, the BLOOD VESSELS, and the NERVE TISSUE.
Minor hemoglobin components of human erythrocytes designated A1a, A1b, and A1c. Hemoglobin A1c is most important since its sugar moiety is glucose covalently bound to the terminal amino acid of the beta chain. Since normal glycohemoglobin concentrations exclude marked blood glucose fluctuations over the preceding three to four weeks, the concentration of glycosylated hemoglobin A is a more reliable index of the blood sugar average over a long period of time.
Territory in north central Australia, between the states of Queensland and Western Australia. Its capital is Darwin.
Examination of urine by chemical, physical, or microscopic means. Routine urinalysis usually includes performing chemical screening tests, determining specific gravity, observing any unusual color or odor, screening for bacteriuria, and examining the sediment microscopically.
Inflammation of any part of the KIDNEY.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Individuals whose ancestral origins are in the islands of the central and South Pacific, including Micronesia, Melanesia, Polynesia, and traditionally Australasia.
An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.
Pathological processes of the KIDNEY without inflammatory or neoplastic components. Nephrosis may be a primary disorder or secondary complication of other diseases. It is characterized by the NEPHROTIC SYNDROME indicating the presence of PROTEINURIA and HYPOALBUMINEMIA with accompanying EDEMA.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Excision of kidney.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Government required written and driving test given to individuals prior to obtaining an operator's license.
The thin membranous structure supporting the adjoining glomerular capillaries. It is composed of GLOMERULAR MESANGIAL CELLS and their EXTRACELLULAR MATRIX.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM.
Laboratory rats that have been produced from a genetically manipulated rat EGG or rat EMBRYO, MAMMALIAN. They contain genes from another species.
An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals.
Smooth muscle-like cells adhering to the wall of the small blood vessels of the KIDNEY at the glomerulus and along the vascular pole of the glomerulus in the JUXTAGLOMERULAR APPARATUS. They are myofibroblasts with contractile and phagocytic properties. These cells and their MESANGIAL EXTRACELLULAR MATRIX constitute the GLOMERULAR MESANGIUM.
Animals that are produced through selective breeding to eliminate genetic background differences except for a single or few specific loci. They are used to investigate the contribution of genetic background differences to PHENOTYPE.
A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
The appearance of an abnormally large amount of GLUCOSE in the urine, such as more than 500 mg/day in adults. It can be due to HYPERGLYCEMIA or genetic defects in renal reabsorption (RENAL GLYCOSURIA).
A subclass of EXOPEPTIDASES that act on the free N terminus end of a polypeptide liberating a single amino acid residue. EC 3.4.11.
A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.
A darkly stained mat-like EXTRACELLULAR MATRIX (ECM) that separates cell layers, such as EPITHELIUM from ENDOTHELIUM or a layer of CONNECTIVE TISSUE. The ECM layer that supports an overlying EPITHELIUM or ENDOTHELIUM is called basal lamina. Basement membrane (BM) can be formed by the fusion of either two adjacent basal laminae or a basal lamina with an adjacent reticular lamina of connective tissue. BM, composed mainly of TYPE IV COLLAGEN; glycoprotein LAMININ; and PROTEOGLYCAN, provides barriers as well as channels between interacting cell layers.
A group of differentiation surface antigens, among the first to be discovered on thymocytes and T-lymphocytes. Originally identified in the mouse, they are also found in other species including humans, and are expressed on brain neurons and other cells.
PUROMYCIN derivative that lacks the methoxyphenylalanyl group on the amine of the sugar ring. It is an antibiotic with antineoplastic properties and can cause nephrosis.

Prevalence of peripheral arterial disease and associated risk factors in American Indians: the Strong Heart Study. (1/2491)

Studies of peripheral arterial disease (PAD) in minority populations provide researchers with an opportunity to evaluate PAD risk factors and disease severity under different types of conditions. Examination 1 of the Strong Heart Study (1989-1992) provided data on the prevalence of PAD and its risk factors in a sample of American Indians. Participants (N = 4,549) represented 13 tribes located in three geographically diverse centers in the Dakotas, Oklahoma, and Arizona. Participants in this epidemiologic study were aged 45-74 years; 60% were women. Using the single criterion of an ankle brachial index less than 0.9 to define PAD, the prevalence of PAD was approximately 5.3% across centers, with women having slightly higher rates than men. Factors significantly associated with PAD in univariate analyses for both men and women included age, systolic blood pressure, hemoglobin A1c level, albuminuria, fibrinogen level, fasting glucose level, prevalence of diabetes mellitus, and duration of diabetes. Multiple logistic regression analyses were used to predict PAD for women and men combined. Age, systolic blood pressure, current cigarette smoking, pack-years of smoking, albuminuria (micro- and macro-), low density lipoprotein cholesterol level, and fibrinogen level were significantly positively associated with PAD. Current alcohol consumption was significantly negatively associated with PAD. In American Indians, the association of albuminuria with PAD may equal or exceed the association of cigarette smoking with PAD.  (+info)

Acute haemodynamic and proteinuric effects of prednisolone in patients with a nephrotic syndrome. (2/2491)

BACKGROUND: Administration of prednisolone causes an abrupt rise in proteinuria in patients with a nephrotic syndrome. METHODS: To clarify the mechanisms responsible for this increase in proteinuria we have performed a placebo controlled study in 26 patients with a nephrotic syndrome. Systemic and renal haemodynamics and urinary protein excretion were measured after prednisolone and after placebo. RESULTS: After i.v. administration of 125-150 mg prednisolone total proteinuria increased from 6.66+/-4.42 to 9.37+/-6.07 mg/min (P<0.001). By analysing the excretion of proteins with different charge and weight (albumin, transferrin, IgG, IgG4 and beta2-microglobulin) it became apparent that the increase of proteinuria was the result of a change in size selectivity rather than a change in glomerular charge selectivity or tubular protein reabsorption. Glomerular filtration rate rose from 83+/-34 ml to 95+/-43 ml/min (P<0.001) after 5 h, whereas effective renal plasma flow and endogenous creatinine clearance remained unchanged. As a result filtration fraction was increased, compatible with an increased glomerular pressure, which probably contributes to the size selectivity changes. Since corticosteroids affect both the renin-angiotensin system and renal prostaglandins, we have evaluated the effects of prednisolone on proteinuria after pretreatment with 3 months of the angiotensin-converting enzyme inhibitor lisinopril or after 2 weeks of the prostaglandin synthesis inhibitor indomethacin. Neither drug had any effect on prednisolone-induced increases of proteinuria. CONCLUSIONS: Prednisolone increases proteinuria by changing the size selective barrier of the glomerular capillary. Neither the renin-angiotensin axis nor prostaglandins seem to be involved in these effects of prednisolone on proteinuria.  (+info)

Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. (3/2491)

BACKGROUND: Increased renal resistance detected by ultrasound (US) Doppler has been reported in severe essential hypertension (EH) and recently was shown to correlate with the degree of renal impairment in hypertensive patients with chronic renal failure. However, the pathophysiological significance of this finding is still controversial. METHODS: In a group of 211 untreated patients with EH, we evaluated renal resistive index (RI) by US Doppler of interlobar arteries and early signs of target organ damage (TOD). Albuminuria was measured as the albumin to creatinine ratio (ACR) in three non-consecutive first morning urine samples. Left ventricular mass was evaluated by M-B mode echocardiography, and carotid wall thickness (IMT) by high resolution US scan. RESULTS: RI was positively correlated with age (r=0.25, P=0.003) and systolic blood pressure (SBP) (r=0.2, P=0.02) and with signs of early TOD, namely ACR (r=0.22, P=0.01) and IMT (r=0.17, P<0.05), and inversely correlated with renal volume (r=-0.22, P=0.01) and diastolic blood pressure (r=-0.23, P=0.006). Multiple linear regression analysis demonstrated that age, gender, ACR and SBP independently influence RI and together account for approximately 20% of its variations (F=8.153, P<0.0001). When clinical data were analysed according to the degree of RI, the patients in the top quartile were found to be older (P<0.05) and with higher SBP (P<0.05) as well as early signs of TOD, namely increased ACR (P<0.002) and IMT (P<0.005 by ANOVA), despite similar body mass index, uric acid, fasting blood glucose, lipid profile and duration of hypertension. Furthermore, patients with higher RI showed a significantly higher prevalence of microalbuminuria (13 vs 12 vs 3 vs 33% chi2=11.72, P=0.008) and left ventricular hypertrophy (40 vs 43 vs 32 vs 60%, chi2=9.25, P<0.05). CONCLUSIONS: Increased RI is associated with early signs of TOD in EH and could be a marker of intrarenal atherosclerosis.  (+info)

Cardiovascular, endocrine, and renal effects of urodilatin in normal humans. (4/2491)

Effects of urodilatin (5, 10, 20, and 40 ng. kg-1. min-1) infused over 2 h on separate study days were studied in eight normal subjects with use of a randomized, double-blind protocol. All doses decreased renal plasma flow (hippurate clearance, 13-37%) and increased fractional Li+ clearance (7-22%) and urinary Na+ excretion (by 30, 76, 136, and 99% at 5, 10, 20, and 40 ng. kg-1. min-1, respectively). Glomerular filtration rate did not increase significantly with any dose. The two lowest doses decreased cardiac output (7 and 16%) and stroke volume (10 and 20%) without changing mean arterial blood pressure and heart rate. The two highest doses elicited larger decreases in stroke volume (17 and 21%) but also decreased blood pressure (6 and 14%) and increased heart rate (15 and 38%), such that cardiac output remained unchanged. Hematocrit and plasma protein concentration increased with the three highest doses. The renin-angiotensin-aldosterone system was inhibited by the three lowest doses but activated by the hypotensive dose of 40 ng. kg-1. min-1. Plasma vasopressin increased by factors of up to 5 during infusion of the three highest doses. Atrial natriuretic peptide immunoreactivity (including urodilatin) and plasma cGMP increased dose dependently. The urinary excretion rate of albumin was elevated up to 15-fold (37 +/- 17 micrograms/min). Use of a newly developed assay revealed that baseline urinary urodilatin excretion rate was low (<10 pg/min) and that fractional excretion of urodilatin remained below 0.1%. The results indicate that even moderately natriuretic doses of urodilatin exert protracted effects on systemic hemodynamic, endocrine, and renal functions, including decreases in cardiac output and renal blood flow, without changes in arterial pressure or glomerular filtration rate, and that filtered urodilatin is almost completely removed by the renal tubules.  (+info)

Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. (5/2491)

Microalbuminuria (MA) is associated with increased cardiovascular and all-cause mortality. It has been proposed that MA reflects generalized atherosclerosis and may thus predict mortality. To investigate this hypothesis, we studied the associations between, on the one hand, MA and peripheral arterial disease (PAD), a generally accepted marker of generalized atherosclerosis, and, on the other hand, cardiovascular and all-cause mortality in an age-, sex-, and glucose tolerance-stratified sample (n=631) of a population-based cohort aged 50 to 75 years followed prospectively for 5 years. At baseline, the albumin-to-creatinine ratio (ACR) was measured in an overnight spot urine sample; MA was defined as ACR >2.0 mg/mmol. PAD was defined as an ankle-brachial pressure index below 0.90 and/or a history of a peripheral arterial bypass or amputation. After 5 years of follow-up, 58 subjects had died (24 of cardiovascular causes). Both MA and PAD were associated with a 4-fold increase in cardiovascular mortality. After adjusting for age, sex, diabetes mellitus, hypertension, levels of total and HDL-cholesterol and triglyceride, body mass index, smoking habits, and preexistent ischemic heart disease, the relative risks (RR) (95% confidence intervals) were 3.2 (1.3 to 8.1) for MA and 2.4 (0.9 to 6.1) for PAD. When both MA and PAD were included in the multivariate analysis, the RRs were 2.9 (1.1 to 7.3) for MA and 2.0 (0.7 to 5.7) for PAD. MA and PAD were both associated with an about 2-fold increase in all-cause mortality. The RRs of all-cause mortality associated with MA and PAD were about 4 times higher among hypertensive than among normotensive subjects. We conclude that both MA and PAD are associated with an increased risk of cardiovascular mortality. MA and PAD are mutually independent risk indicators. The associations of MA and PAD with all-cause mortality are somewhat weaker. They are more pronounced in the presence of hypertension than in its absence. These data suggest that MA affects mortality risk through a mechanism different from generalized atherosclerosis.  (+info)

Chronic bradykinin infusion and receptor blockade in angiotensin II hypertension in rats. (6/2491)

The influence of endogenous bradykinin(BK) on the control of arterial pressure and the development of cardiac hypertrophy was assessed in chronically angiotensin II(Ang II)-infused rats (200 ng. kg-1. min-1) through the effects of concomitant infusion of 3 doses of BK (15 ng. kg-1. d-1, 100 ng. kg-1. d-1 and 100 ng. kg-1. min-1 ie, 144 000 ng. kg-1. d-1) or BK-blockade by Hoe140 (300 microg. kg-1. d-1) for 10 days. In Ang II-infused rats, tail-cuff pressure increased from 124+/-3 to 174+/-6 mm Hg (P<0.001). The pressor effect of Ang II was not affected by simultaneous infusion of BK or Hoe140. At the end of the experiments, cardiac mass was higher in rats infused with Ang II alone (3.56+/-0.10 versus 2.89+/-0.05 mg/g in untreated controls, P<0.01) and the development of cardiac hypertrophy was not modified by administration of the 3 doses of BK or Hoe140. In addition, the fall in cardiac output associated with Ang II was prevented only by the moderate and high doses of BK, mainly through an increase in stroke volume and a decrease in total peripheral resistance. In the same way, the renal vasoconstrictor effect of Ang II was abolished by the medium and high dose of BK. Hoe140 did not affect cardiac output or renal blood flow in this model. No influence of BK or Hoe140 on the increase in albuminuria induced by Ang II was detected. In conclusion, exogenous BK may oppose the effect of Ang II on vascular tone, but it cannot prevent hypertension and target-organ damage associated with this experimental model of hypertension, even at a very high dose.  (+info)

Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. (7/2491)

OBJECTIVE: To evaluate kidney function 7 years after the end of treatment with cyclosporine A (CsA) (initial dosage of 9.3 tapered off to 7.0 mg.kg-1.day-1) in young patients (mean age 20 years) with newly diagnosed type 1 diabetes participating in a randomized, double-blind, placebo-controlled CsA trial. RESEARCH DESIGN AND METHODS: In this study, 21 patients received CsA for 12.5 +/- 4.0 months (mean +/- SD) and 19 patients received placebo for 14.4 +/- 3.8 months. The two groups were similar with regard to mean arterial blood pressure (BP), urinary albumin excretion rate (UAER), serum creatinine, and estimated glomerular filtration rate (GFR [Cockcroft and Gault]) at initiation of CsA treatment (baseline). HbA1c (mean +/- SEM) during 7 years of follow-up was also the same: 8.7 +/- 0.4 vs. 8.3 +/- 0.4% in the CsA and placebo groups, respectively. RESULTS: During the 7 years after cessation of study medication, two CsA group patients and one control patient were lost to follow-up. One placebo-treated patient developed IgA nephropathy (biopsy proven) and was excluded. Four CsA-treated patients developed persistently elevated UAER > 30 mg/24 h (n = 3 with microalbuminuria), whereas all the 17 placebo-treated patients had normal UAER (< 30 mg/24 h) after 7 years of follow-up. At the end of follow-up, the CsA group had a more pronounced rise in UAER: 2.5-fold (95% CI 1.4-4.5) higher than baseline value vs. 1.1-fold (0.7-1.7) in the placebo-treated group (P < 0.05). Estimated GFR (ml.min-1.1.73 m-2) declined from baseline to end of follow-up (1994) by 6.3 +/- 6.0 in the former CsA group, whereas it rose by 7.4 +/- 5.0 in the placebo group (P = 0.05). In 1994, 24-h blood pressure was nearly the same: 131/77 +/- 4/2 vs. 127/75 +/- 2/2 mmHg (NS) in the CsA and placebo groups, respectively. Five randomly selected CsA-treated patients had a kidney biopsy performed shortly after the CsA treatment was stopped. Interstitial fibrosis/tubular atrophy and/or arteriolopathy were present in two subjects who both subsequently developed persistent microalbuminuria. CONCLUSIONS: The results of our 7-year follow-up study suggested that short-lasting CsA treatment in young, newly diagnosed type 1 diabetic patients accelerated the rate of progression in UAER and tended to induce a loss in kidney function. Longer term follow-up is mandatory to clarify whether CsA-treated patients are at increased risk of developing clinical nephropathy.  (+info)

Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. (8/2491)

OBJECTIVE: The predictive value of microalbuminuria (MA) in children with type 1 diabetes has not been defined. We describe the natural history of MA in a large cohort of children recruited at diagnosis of type 1 diabetes. RESEARCH DESIGN AND METHODS: Between 1985 and 1996, 514 children (279 male) who developed type 1 diabetes before the age of 16 years (91% of those eligible from a region where ascertainment of new cases is 95%) were recruited for a longitudinal study with central annual assessment of HbAlc and albumin excretion (three urine samples). Dropout rates have been < 1% per year, and 287 children have been followed for > 4.5 years. RESULTS: MA (defined as albumin-to-creatinine ratio > or = 3.5 and > or = 4.0 mg/mmol in boys and girls, respectively) developed in 63 (12.8%) and was persistent in 22 (4.8%) of the subjects. The cumulative probability (based on the Kaplan-Meier method) for developing MA was 40% after 11 years. HbAlc was worse in those who developed MA than in others (mean difference +/- SEM: 1.1% +/- 0.2, P < 0.001). In subjects who had been 5-11 years of age when their diabetes was diagnosed, the appearance of MA was delayed until puberty, whereas of those whose age was < 5 years at diagnosis of diabetes, 5 of 11 (45%) developed MA before puberty. The adjusted proportional probability (Cox model) of MA was greater for female subjects (200%), after pubertal onset (310%), and with greater HbAlc (36% increase for every 1% increase in HbAlc). Despite earlier differences based on age at diagnosis of diabetes (< 5, 5-11, and > 11 years), the overall cumulative risks in these groups were similar (38 vs. 29 vs. 39%, respectively) after 10 years' duration of diabetes. CONCLUSIONS: Prepubertal duration of diabetes and prepubertal hyperglycemia contribute to the risk of postpubertal MA. The differences in rates of development of MA relating to HbAlc, sex, and age at diagnosis relative to puberty may have long-term consequences for the risk of subsequent nephropathy and for cardiovascular risk.  (+info)

Albuminuria is often associated with conditions such as diabetes, high blood pressure, and kidney disease, as these conditions can damage the kidneys and cause albumin to leak into the urine. It is also a common finding in people with chronic kidney disease (CKD), as the damaged kidneys are unable to filter out the excess protein.

If left untreated, albuminuria can lead to complications such as kidney failure, cardiovascular disease, and an increased risk of death. Treatment options for albuminuria include medications to lower blood pressure and control blood sugar levels, as well as dietary changes and lifestyle modifications. In severe cases, dialysis or kidney transplantation may be necessary.

In summary, albuminuria is the presence of albumin in the urine, which can be an indicator of kidney damage or disease. It is often associated with conditions such as diabetes and high blood pressure, and can lead to complications if left untreated.

There are several types of diabetic nephropathy, including:

1. Mesangial proliferative glomerulonephritis: This is the most common type of diabetic nephropathy and is characterized by an overgrowth of cells in the mesangium, a part of the glomerulus (the blood-filtering unit of the kidney).
2. Segmental sclerosis: This type of diabetic nephropathy involves the hardening of some parts of the glomeruli, leading to decreased kidney function.
3. Fibrotic glomerulopathy: This is a rare form of diabetic nephropathy that is characterized by the accumulation of fibrotic tissue in the glomeruli.
4. Membranous nephropathy: This type of diabetic nephropathy involves the deposition of immune complexes (antigen-antibody complexes) in the glomeruli, leading to inflammation and damage to the kidneys.
5. Minimal change disease: This is a rare form of diabetic nephropathy that is characterized by minimal changes in the glomeruli, but with significant loss of kidney function.

The symptoms of diabetic nephropathy can be non-specific and may include proteinuria (excess protein in the urine), hematuria (blood in the urine), and decreased kidney function. Diagnosis is typically made through a combination of physical examination, medical history, laboratory tests, and imaging studies such as ultrasound or CT scans.

Treatment for diabetic nephropathy typically involves managing blood sugar levels through lifestyle changes (such as diet and exercise) and medication, as well as controlling high blood pressure and other underlying conditions. In severe cases, dialysis or kidney transplantation may be necessary. Early detection and management of diabetic nephropathy can help slow the progression of the disease and improve outcomes for patients with this condition.

Type 2 diabetes can be managed through a combination of diet, exercise, and medication. In some cases, lifestyle changes may be enough to control blood sugar levels, while in other cases, medication or insulin therapy may be necessary. Regular monitoring of blood sugar levels and follow-up with a healthcare provider are important for managing the condition and preventing complications.

Common symptoms of type 2 diabetes include:

* Increased thirst and urination
* Fatigue
* Blurred vision
* Cuts or bruises that are slow to heal
* Tingling or numbness in the hands and feet
* Recurring skin, gum, or bladder infections

If left untreated, type 2 diabetes can lead to a range of complications, including:

* Heart disease and stroke
* Kidney damage and failure
* Nerve damage and pain
* Eye damage and blindness
* Foot damage and amputation

The exact cause of type 2 diabetes is not known, but it is believed to be linked to a combination of genetic and lifestyle factors, such as:

* Obesity and excess body weight
* Lack of physical activity
* Poor diet and nutrition
* Age and family history
* Certain ethnicities (e.g., African American, Hispanic/Latino, Native American)
* History of gestational diabetes or delivering a baby over 9 lbs.

There is no cure for type 2 diabetes, but it can be managed and controlled through a combination of lifestyle changes and medication. With proper treatment and self-care, people with type 2 diabetes can lead long, healthy lives.

Types of Kidney Diseases:

1. Acute Kidney Injury (AKI): A sudden and reversible loss of kidney function that can be caused by a variety of factors, such as injury, infection, or medication.
2. Chronic Kidney Disease (CKD): A gradual and irreversible loss of kidney function that can lead to end-stage renal disease (ESRD).
3. End-Stage Renal Disease (ESRD): A severe and irreversible form of CKD that requires dialysis or a kidney transplant.
4. Glomerulonephritis: An inflammation of the glomeruli, the tiny blood vessels in the kidneys that filter waste products.
5. Interstitial Nephritis: An inflammation of the tissue between the tubules and blood vessels in the kidneys.
6. Kidney Stone Disease: A condition where small, hard mineral deposits form in the kidneys and can cause pain, bleeding, and other complications.
7. Pyelonephritis: An infection of the kidneys that can cause inflammation, damage to the tissues, and scarring.
8. Renal Cell Carcinoma: A type of cancer that originates in the cells of the kidney.
9. Hemolytic Uremic Syndrome (HUS): A condition where the immune system attacks the platelets and red blood cells, leading to anemia, low platelet count, and damage to the kidneys.

Symptoms of Kidney Diseases:

1. Blood in urine or hematuria
2. Proteinuria (excess protein in urine)
3. Reduced kidney function or renal insufficiency
4. Swelling in the legs, ankles, and feet (edema)
5. Fatigue and weakness
6. Nausea and vomiting
7. Abdominal pain
8. Frequent urination or polyuria
9. Increased thirst and drinking (polydipsia)
10. Weight loss

Diagnosis of Kidney Diseases:

1. Physical examination
2. Medical history
3. Urinalysis (test of urine)
4. Blood tests (e.g., creatinine, urea, electrolytes)
5. Imaging studies (e.g., X-rays, CT scans, ultrasound)
6. Kidney biopsy
7. Other specialized tests (e.g., 24-hour urinary protein collection, kidney function tests)

Treatment of Kidney Diseases:

1. Medications (e.g., diuretics, blood pressure medication, antibiotics)
2. Diet and lifestyle changes (e.g., low salt intake, increased water intake, physical activity)
3. Dialysis (filtering waste products from the blood when the kidneys are not functioning properly)
4. Kidney transplantation ( replacing a diseased kidney with a healthy one)
5. Other specialized treatments (e.g., plasmapheresis, hemodialysis)

Prevention of Kidney Diseases:

1. Maintaining a healthy diet and lifestyle
2. Monitoring blood pressure and blood sugar levels
3. Avoiding harmful substances (e.g., tobacco, excessive alcohol consumption)
4. Managing underlying medical conditions (e.g., diabetes, high blood pressure)
5. Getting regular check-ups and screenings

Early detection and treatment of kidney diseases can help prevent or slow the progression of the disease, reducing the risk of complications and improving quality of life. It is important to be aware of the signs and symptoms of kidney diseases and seek medical attention if they are present.

Proteinuria is usually diagnosed by a urine protein-to-creatinine ratio (P/C ratio) or a 24-hour urine protein collection. The amount and duration of proteinuria can help distinguish between different underlying causes and predict prognosis.

Proteinuria can have significant clinical implications, as it is associated with increased risk of cardiovascular disease, kidney damage, and malnutrition. Treatment of the underlying cause can help reduce or eliminate proteinuria.

There are two main types of Renal Insufficiency:

1. Acute Kidney Injury (AKI): This is a sudden and reversible decrease in kidney function, often caused by injury, sepsis, or medication toxicity. AKI can resolve with appropriate treatment and supportive care.
2. Chronic Renal Insufficiency (CRI): This is a long-standing and irreversible decline in kidney function, often caused by diabetes, high blood pressure, or chronic kidney disease. CRI can lead to ESRD if left untreated.

Signs and symptoms of Renal Insufficiency may include:

* Decreased urine output
* Swelling in the legs and ankles (edema)
* Fatigue
* Nausea and vomiting
* Shortness of breath (dyspnea)
* Pain in the back, flank, or abdomen

Diagnosis of Renal Insufficiency is typically made through a combination of physical examination, medical history, laboratory tests, and imaging studies. Laboratory tests may include urinalysis, blood urea nitrogen (BUN) and creatinine levels, and a 24-hour urine protein collection. Imaging studies, such as ultrasound or CT scans, may be used to evaluate the kidneys and rule out other possible causes of the patient's symptoms.

Treatment of Renal Insufficiency depends on the underlying cause and the severity of the condition. Treatment may include medications to control blood pressure, manage fluid balance, and reduce proteinuria (excess protein in the urine). In some cases, dialysis or a kidney transplant may be necessary.

Prevention of Renal Insufficiency includes managing underlying conditions such as diabetes and hypertension, avoiding nephrotoxic medications and substances, and maintaining a healthy diet and lifestyle. Early detection and treatment of acute kidney injury can also help prevent the development of chronic renal insufficiency.

In conclusion, Renal Insufficiency is a common condition that can have significant consequences if left untreated. It is important for healthcare providers to be aware of the causes, symptoms, and diagnosis of Renal Insufficiency, as well as the treatment and prevention strategies available. With appropriate management, many patients with Renal Insufficiency can recover and maintain their kidney function over time.

The symptoms of chronic renal insufficiency can be subtle and may develop gradually over time. They may include fatigue, weakness, swelling in the legs and ankles, nausea, vomiting, and difficulty concentrating. As the disease progresses, patients may experience shortness of breath, heart failure, and peripheral artery disease.

Chronic renal insufficiency is diagnosed through blood tests that measure the level of waste products in the blood, such as creatinine and urea. Imaging studies, such as ultrasound and CT scans, may also be used to evaluate the kidneys and detect any damage or scarring.

Treatment for chronic renal insufficiency focuses on slowing the progression of the disease and managing its symptoms. This may include medications to control high blood pressure, diabetes, and anemia, as well as dietary changes and fluid restrictions. In severe cases, dialysis or kidney transplantation may be necessary.

Prevention of chronic renal insufficiency involves managing underlying conditions such as diabetes and hypertension, maintaining a healthy diet and exercise routine, and avoiding substances that can damage the kidneys, such as tobacco and excessive alcohol consumption. Early detection and treatment of kidney disease can help prevent the progression to chronic renal insufficiency.

The term "segmental" refers to the fact that the scarring or hardening occurs in a specific segment of the glomerulus. Focal segmental glomerulosclerosis can be caused by a variety of factors, including diabetes, high blood pressure, and certain infections or injuries.

Symptoms of focal segmental glomerulosclerosis may include proteinuria (excess protein in the urine), hematuria (blood in the urine), and decreased kidney function. Treatment options vary depending on the underlying cause, but may include medications to control high blood pressure or diabetes, as well as immunosuppressive drugs in cases where the condition is caused by an autoimmune disorder. In severe cases, dialysis or kidney transplantation may be necessary.

There are two types of hypertension:

1. Primary Hypertension: This type of hypertension has no identifiable cause and is also known as essential hypertension. It accounts for about 90% of all cases of hypertension.
2. Secondary Hypertension: This type of hypertension is caused by an underlying medical condition or medication. It accounts for about 10% of all cases of hypertension.

Some common causes of secondary hypertension include:

* Kidney disease
* Adrenal gland disorders
* Hormonal imbalances
* Certain medications
* Sleep apnea
* Cocaine use

There are also several risk factors for hypertension, including:

* Age (the risk increases with age)
* Family history of hypertension
* Obesity
* Lack of exercise
* High sodium intake
* Low potassium intake
* Stress

Hypertension is often asymptomatic, and it can cause damage to the blood vessels and organs over time. Some potential complications of hypertension include:

* Heart disease (e.g., heart attacks, heart failure)
* Stroke
* Kidney disease (e.g., chronic kidney disease, end-stage renal disease)
* Vision loss (e.g., retinopathy)
* Peripheral artery disease

Hypertension is typically diagnosed through blood pressure readings taken over a period of time. Treatment for hypertension may include lifestyle changes (e.g., diet, exercise, stress management), medications, or a combination of both. The goal of treatment is to reduce the risk of complications and improve quality of life.

Types of Experimental Diabetes Mellitus include:

1. Streptozotocin-induced diabetes: This type of EDM is caused by administration of streptozotocin, a chemical that damages the insulin-producing beta cells in the pancreas, leading to high blood sugar levels.
2. Alloxan-induced diabetes: This type of EDM is caused by administration of alloxan, a chemical that also damages the insulin-producing beta cells in the pancreas.
3. Pancreatectomy-induced diabetes: In this type of EDM, the pancreas is surgically removed or damaged, leading to loss of insulin production and high blood sugar levels.

Experimental Diabetes Mellitus has several applications in research, including:

1. Testing new drugs and therapies for diabetes treatment: EDM allows researchers to evaluate the effectiveness of new treatments on blood sugar control and other physiological processes.
2. Studying the pathophysiology of diabetes: By inducing EDM in animals, researchers can study the progression of diabetes and its effects on various organs and tissues.
3. Investigating the role of genetics in diabetes: Researchers can use EDM to study the effects of genetic mutations on diabetes development and progression.
4. Evaluating the efficacy of new diagnostic techniques: EDM allows researchers to test new methods for diagnosing diabetes and monitoring blood sugar levels.
5. Investigating the complications of diabetes: By inducing EDM in animals, researchers can study the development of complications such as retinopathy, nephropathy, and cardiovascular disease.

In conclusion, Experimental Diabetes Mellitus is a valuable tool for researchers studying diabetes and its complications. The technique allows for precise control over blood sugar levels and has numerous applications in testing new treatments, studying the pathophysiology of diabetes, investigating the role of genetics, evaluating new diagnostic techniques, and investigating complications.

A type of hypertension that is caused by a problem with the kidneys. It can be acute or chronic and may be associated with other conditions such as glomerulonephritis, pyelonephritis, or polycystic kidney disease. Symptoms include proteinuria, hematuria, and elevated blood pressure. Treatment options include diuretics, ACE inhibitors, and angiotensin II receptor blockers.

Note: Renal hypertension is also known as renal artery hypertension.

Symptoms of type 1 diabetes can include increased thirst and urination, blurred vision, fatigue, weight loss, and skin infections. If left untreated, type 1 diabetes can lead to serious complications such as kidney damage, nerve damage, and blindness.

Type 1 diabetes is diagnosed through a combination of physical examination, medical history, and laboratory tests such as blood glucose measurements and autoantibody tests. Treatment typically involves insulin therapy, which can be administered via injections or an insulin pump, as well as regular monitoring of blood glucose levels and appropriate lifestyle modifications such as a healthy diet and regular exercise.

A condition in which the kidneys gradually lose their function over time, leading to the accumulation of waste products in the body. Also known as chronic kidney disease (CKD).

Prevalence:

Chronic kidney failure affects approximately 20 million people worldwide and is a major public health concern. In the United States, it is estimated that 1 in 5 adults has CKD, with African Americans being disproportionately affected.

Causes:

The causes of chronic kidney failure are numerous and include:

1. Diabetes: High blood sugar levels can damage the kidneys over time.
2. Hypertension: Uncontrolled high blood pressure can cause damage to the blood vessels in the kidneys.
3. Glomerulonephritis: An inflammation of the glomeruli, the tiny blood vessels in the kidneys that filter waste and excess fluids from the blood.
4. Interstitial nephritis: Inflammation of the tissue between the kidney tubules.
5. Pyelonephritis: Infection of the kidneys, usually caused by bacteria or viruses.
6. Polycystic kidney disease: A genetic disorder that causes cysts to grow on the kidneys.
7. Obesity: Excess weight can increase blood pressure and strain on the kidneys.
8. Family history: A family history of kidney disease increases the risk of developing chronic kidney failure.

Symptoms:

Early stages of chronic kidney failure may not cause any symptoms, but as the disease progresses, symptoms can include:

1. Fatigue: Feeling tired or weak.
2. Swelling: In the legs, ankles, and feet.
3. Nausea and vomiting: Due to the buildup of waste products in the body.
4. Poor appetite: Loss of interest in food.
5. Difficulty concentrating: Cognitive impairment due to the buildup of waste products in the brain.
6. Shortness of breath: Due to fluid buildup in the lungs.
7. Pain: In the back, flank, or abdomen.
8. Urination changes: Decreased urine production, dark-colored urine, or blood in the urine.
9. Heart problems: Chronic kidney failure can increase the risk of heart disease and heart attack.

Diagnosis:

Chronic kidney failure is typically diagnosed based on a combination of physical examination findings, medical history, laboratory tests, and imaging studies. Laboratory tests may include:

1. Blood urea nitrogen (BUN) and creatinine: Waste products in the blood that increase with decreased kidney function.
2. Electrolyte levels: Imbalances in electrolytes such as sodium, potassium, and phosphorus can indicate kidney dysfunction.
3. Kidney function tests: Measurement of glomerular filtration rate (GFR) to determine the level of kidney function.
4. Urinalysis: Examination of urine for protein, blood, or white blood cells.

Imaging studies may include:

1. Ultrasound: To assess the size and shape of the kidneys, detect any blockages, and identify any other abnormalities.
2. Computed tomography (CT) scan: To provide detailed images of the kidneys and detect any obstructions or abscesses.
3. Magnetic resonance imaging (MRI): To evaluate the kidneys and detect any damage or scarring.

Treatment:

Treatment for chronic kidney failure depends on the underlying cause and the severity of the disease. The goals of treatment are to slow progression of the disease, manage symptoms, and improve quality of life. Treatment may include:

1. Medications: To control high blood pressure, lower cholesterol levels, reduce proteinuria, and manage anemia.
2. Diet: A healthy diet that limits protein intake, controls salt and water intake, and emphasizes low-fat dairy products, fruits, and vegetables.
3. Fluid management: Monitoring and control of fluid intake to prevent fluid buildup in the body.
4. Dialysis: A machine that filters waste products from the blood when the kidneys are no longer able to do so.
5. Transplantation: A kidney transplant may be considered for some patients with advanced chronic kidney failure.

Complications:

Chronic kidney failure can lead to several complications, including:

1. Heart disease: High blood pressure and anemia can increase the risk of heart disease.
2. Anemia: A decrease in red blood cells can cause fatigue, weakness, and shortness of breath.
3. Bone disease: A disorder that can lead to bone pain, weakness, and an increased risk of fractures.
4. Electrolyte imbalance: Imbalances of electrolytes such as potassium, phosphorus, and sodium can cause muscle weakness, heart arrhythmias, and other complications.
5. Infections: A decrease in immune function can increase the risk of infections.
6. Nutritional deficiencies: Poor appetite, nausea, and vomiting can lead to malnutrition and nutrient deficiencies.
7. Cardiovascular disease: High blood pressure, anemia, and other complications can increase the risk of cardiovascular disease.
8. Pain: Chronic kidney failure can cause pain, particularly in the back, flank, and abdomen.
9. Sleep disorders: Insomnia, sleep apnea, and restless leg syndrome are common complications.
10. Depression and anxiety: The emotional burden of chronic kidney failure can lead to depression and anxiety.

Disease progression can be classified into several types based on the pattern of worsening:

1. Chronic progressive disease: In this type, the disease worsens steadily over time, with a gradual increase in symptoms and decline in function. Examples include rheumatoid arthritis, osteoarthritis, and Parkinson's disease.
2. Acute progressive disease: This type of disease worsens rapidly over a short period, often followed by periods of stability. Examples include sepsis, acute myocardial infarction (heart attack), and stroke.
3. Cyclical disease: In this type, the disease follows a cycle of worsening and improvement, with periodic exacerbations and remissions. Examples include multiple sclerosis, lupus, and rheumatoid arthritis.
4. Recurrent disease: This type is characterized by episodes of worsening followed by periods of recovery. Examples include migraine headaches, asthma, and appendicitis.
5. Catastrophic disease: In this type, the disease progresses rapidly and unpredictably, with a poor prognosis. Examples include cancer, AIDS, and organ failure.

Disease progression can be influenced by various factors, including:

1. Genetics: Some diseases are inherited and may have a predetermined course of progression.
2. Lifestyle: Factors such as smoking, lack of exercise, and poor diet can contribute to disease progression.
3. Environmental factors: Exposure to toxins, allergens, and other environmental stressors can influence disease progression.
4. Medical treatment: The effectiveness of medical treatment can impact disease progression, either by slowing or halting the disease process or by causing unintended side effects.
5. Co-morbidities: The presence of multiple diseases or conditions can interact and affect each other's progression.

Understanding the type and factors influencing disease progression is essential for developing effective treatment plans and improving patient outcomes.

1. Coronary artery disease: The narrowing or blockage of the coronary arteries, which supply blood to the heart.
2. Heart failure: A condition in which the heart is unable to pump enough blood to meet the body's needs.
3. Arrhythmias: Abnormal heart rhythms that can be too fast, too slow, or irregular.
4. Heart valve disease: Problems with the heart valves that control blood flow through the heart.
5. Heart muscle disease (cardiomyopathy): Disease of the heart muscle that can lead to heart failure.
6. Congenital heart disease: Defects in the heart's structure and function that are present at birth.
7. Peripheral artery disease: The narrowing or blockage of blood vessels that supply oxygen and nutrients to the arms, legs, and other organs.
8. Deep vein thrombosis (DVT): A blood clot that forms in a deep vein, usually in the leg.
9. Pulmonary embolism: A blockage in one of the arteries in the lungs, which can be caused by a blood clot or other debris.
10. Stroke: A condition in which there is a lack of oxygen to the brain due to a blockage or rupture of blood vessels.

The symptoms of glomerulonephritis can vary depending on the underlying cause of the disease, but may include:

* Blood in the urine (hematuria)
* Proteinuria (excess protein in the urine)
* Reduced kidney function
* Swelling in the legs and ankles (edema)
* High blood pressure

Glomerulonephritis can be caused by a variety of factors, including:

* Infections such as staphylococcal or streptococcal infections
* Autoimmune disorders such as lupus or rheumatoid arthritis
* Allergic reactions to certain medications
* Genetic defects
* Certain diseases such as diabetes, high blood pressure, and sickle cell anemia

The diagnosis of glomerulonephritis typically involves a physical examination, medical history, and laboratory tests such as urinalysis, blood tests, and kidney biopsy.

Treatment for glomerulonephritis depends on the underlying cause of the disease and may include:

* Antibiotics to treat infections
* Medications to reduce inflammation and swelling
* Diuretics to reduce fluid buildup in the body
* Immunosuppressive medications to suppress the immune system in cases of autoimmune disorders
* Dialysis in severe cases

The prognosis for glomerulonephritis depends on the underlying cause of the disease and the severity of the inflammation. In some cases, the disease may progress to end-stage renal disease, which requires dialysis or a kidney transplant. With proper treatment, however, many people with glomerulonephritis can experience a good outcome and maintain their kidney function over time.

There are several types of diabetic angiopathies, including:

1. Peripheral artery disease (PAD): This occurs when the blood vessels in the legs and arms become narrowed or blocked, leading to reduced blood flow and oxygen supply to the limbs.
2. Peripheral neuropathy: This is damage to the nerves in the hands and feet, which can cause pain, numbness, and weakness.
3. Retinopathy: This is damage to the blood vessels in the retina, which can lead to vision loss and blindness.
4. Nephropathy: This is damage to the kidneys, which can lead to kidney failure and the need for dialysis.
5. Cardiovascular disease: This includes heart attack, stroke, and other conditions that affect the heart and blood vessels.

The risk of developing diabetic angiopathies increases with the duration of diabetes and the level of blood sugar control. Other factors that can increase the risk include high blood pressure, high cholesterol, smoking, and a family history of diabetes-related complications.

Symptoms of diabetic angiopathies can vary depending on the specific type of complication and the location of the affected blood vessels or nerves. Common symptoms include:

* Pain or discomfort in the arms, legs, hands, or feet
* Numbness or tingling sensations in the hands and feet
* Weakness or fatigue in the limbs
* Difficulty healing wounds or cuts
* Vision changes or blindness
* Kidney problems or failure
* Heart attack or stroke

Diagnosis of diabetic angiopathies typically involves a combination of physical examination, medical history, and diagnostic tests such as ultrasound, MRI, or CT scans. Treatment options vary depending on the specific type of complication and may include:

* Medications to control blood sugar levels, high blood pressure, and high cholesterol
* Lifestyle changes such as a healthy diet and regular exercise
* Surgery to repair or bypass affected blood vessels or nerves
* Dialysis for kidney failure
* In some cases, amputation of the affected limb

Preventing diabetic angiopathies involves managing diabetes effectively through a combination of medication, lifestyle changes, and regular medical check-ups. Early detection and treatment can help prevent or delay the progression of complications.

1. Heart Disease: High blood sugar levels can damage the blood vessels and increase the risk of heart disease, which includes conditions like heart attacks, strokes, and peripheral artery disease.
2. Kidney Damage: Uncontrolled diabetes can damage the kidneys over time, leading to chronic kidney disease and potentially even kidney failure.
3. Nerve Damage: High blood sugar levels can damage the nerves in the body, causing numbness, tingling, and pain in the hands and feet. This is known as diabetic neuropathy.
4. Eye Problems: Diabetes can cause changes in the blood vessels of the eyes, leading to vision problems and even blindness. This is known as diabetic retinopathy.
5. Infections: People with diabetes are more prone to developing skin infections, urinary tract infections, and other types of infections due to their weakened immune system.
6. Amputations: Poor blood flow and nerve damage can lead to amputations of the feet or legs if left untreated.
7. Cognitive Decline: Diabetes has been linked to an increased risk of cognitive decline and dementia.
8. Sexual Dysfunction: Men with diabetes may experience erectile dysfunction, while women with diabetes may experience decreased sexual desire and vaginal dryness.
9. Gum Disease: People with diabetes are more prone to developing gum disease and other oral health problems due to their increased risk of infection.
10. Flu and Pneumonia: Diabetes can weaken the immune system, making it easier to catch the flu and pneumonia.

It is important for people with diabetes to manage their condition properly to prevent or delay these complications from occurring. This includes monitoring blood sugar levels regularly, taking medication as prescribed by a doctor, and following a healthy diet and exercise plan. Regular check-ups with a healthcare provider can also help identify any potential complications early on and prevent them from becoming more serious.

Nephritis is often diagnosed through a combination of physical examination, medical history, and laboratory tests such as urinalysis and blood tests. Treatment for nephritis depends on the underlying cause, but may include antibiotics, corticosteroids, and immunosuppressive medications. In severe cases, dialysis may be necessary to remove waste products from the blood.

Some common types of nephritis include:

1. Acute pyelonephritis: This is a type of bacterial infection that affects the kidneys and can cause sudden and severe symptoms.
2. Chronic pyelonephritis: This is a type of inflammation that occurs over a longer period of time, often as a result of recurrent infections or other underlying conditions.
3. Lupus nephritis: This is a type of inflammation that occurs in people with systemic lupus erythematosus (SLE), an autoimmune disorder that can affect multiple organs.
4. IgA nephropathy: This is a type of inflammation that occurs when an antibody called immunoglobulin A (IgA) deposits in the kidneys and causes damage.
5. Mesangial proliferative glomerulonephritis: This is a type of inflammation that affects the mesangium, a layer of tissue in the kidney that helps to filter waste products from the blood.
6. Minimal change disease: This is a type of nephrotic syndrome (a group of symptoms that include proteinuria, or excess protein in the urine) that is caused by inflammation and changes in the glomeruli, the tiny blood vessels in the kidneys that filter waste products from the blood.
7. Membranous nephropathy: This is a type of inflammation that occurs when there is an abnormal buildup of antibodies called immunoglobulin G (IgG) in the glomeruli, leading to damage to the kidneys.
8. Focal segmental glomerulosclerosis: This is a type of inflammation that affects one or more segments of the glomeruli, leading to scarring and loss of function.
9. Post-infectious glomerulonephritis: This is a type of inflammation that occurs after an infection, such as streptococcal infections, and can cause damage to the kidneys.
10. Acute tubular necrosis (ATN): This is a type of inflammation that occurs when there is a sudden loss of blood flow to the kidneys, causing damage to the tubules, which are tiny tubes in the kidneys that help to filter waste products from the blood.

Nephrosis is a condition that affects the function of the kidneys, leading to damage and loss of their filtering ability. It can be caused by a variety of factors and can lead to a range of symptoms and complications. In this article, we will explore the definition and causes of nephrosis, as well as treatment options and outcomes for patients with this condition.

Definition of Nephrosis

Nephrosis is a medical term used to describe damage to the kidneys that leads to a loss of their function. The kidneys play a critical role in filtering waste products and excess fluids from the blood, and when they are not functioning properly, these waste products can build up in the body. Nephrosis can be caused by a variety of factors, including diabetes, high blood pressure, and certain medications.

Causes of Nephrosis

There are several factors that can cause nephrosis. Some of the most common causes include:

1. Diabetes: High blood sugar levels can damage the kidneys over time, leading to nephrosis.
2. High Blood Pressure: Uncontrolled high blood pressure can damage the blood vessels in the kidneys, leading to nephrosis.
3. Medications: Certain medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and certain antibiotics, can be harmful to the kidneys and cause nephrosis.
4. Infections: Severe infections, such as pyelonephritis, can damage the kidneys and lead to nephrosis.
5. Glomerulonephritis: This is a type of inflammation of the glomeruli, the tiny blood vessels in the kidneys that filter waste products from the blood.
6. Interstitial Nephritis: This is a type of inflammation of the tissue between the nephrons, the tiny tubules in the kidneys that filter waste products from the blood.
7. Kidney Disease: Any type of kidney disease, such as polycystic kidney disease or membranous nephropathy, can cause nephrosis.
8. Obesity: Excess weight can increase the risk of developing high blood pressure and diabetes, both of which are leading causes of nephrosis.
9. Family History: A family history of kidney disease increases the risk of developing nephrosis.
10. Age: The risk of developing nephrosis increases with age, especially after the age of 50.

Symptoms of Nephrosis

The symptoms of nephrosis can vary depending on the underlying cause and the severity of the condition. Some common symptoms include:

1. Proteinuria: The presence of protein in the urine, which can be detected by a simple urine test.
2. Hematuria: The presence of blood in the urine, which can be seen with the naked eye or detected by a urine test.
3. Edema: Swelling in the legs, ankles, and feet caused by fluid retention.
4. High Blood Pressure: Hypertension is common in people with nephrosis and can further damage the kidneys.
5. Fatigue: Weakness and fatigue are common symptoms of nephrosis due to anemia and nutrient deficiencies.
6. Nausea and Vomiting: Some people with nephrosis may experience nausea and vomiting due to electrolyte imbalances.
7. Weight Loss: Weight loss can occur in advanced cases of nephrosis as the body is unable to retain enough fluid.
8. Decreased Urine Output: A decrease in urine output can be a sign of nephrosis, especially if it is accompanied by other symptoms such as proteinuria and hematuria.
9. Flank Pain: Some people with nephrosis may experience flank pain, which is pain in the side or back of the abdomen.
10. Pericarditis: Inflammation of the pericardium, the membrane surrounding the heart, can occur in some cases of nephrosis.

It's important to note that not everyone with nephrosis will experience all of these symptoms, and the severity of the disease can vary from person to person. If you suspect you or someone you know may have nephrosis, it is important to seek medical attention as soon as possible for proper diagnosis and treatment.

1) They share similarities with humans: Many animal species share similar biological and physiological characteristics with humans, making them useful for studying human diseases. For example, mice and rats are often used to study diseases such as diabetes, heart disease, and cancer because they have similar metabolic and cardiovascular systems to humans.

2) They can be genetically manipulated: Animal disease models can be genetically engineered to develop specific diseases or to model human genetic disorders. This allows researchers to study the progression of the disease and test potential treatments in a controlled environment.

3) They can be used to test drugs and therapies: Before new drugs or therapies are tested in humans, they are often first tested in animal models of disease. This allows researchers to assess the safety and efficacy of the treatment before moving on to human clinical trials.

4) They can provide insights into disease mechanisms: Studying disease models in animals can provide valuable insights into the underlying mechanisms of a particular disease. This information can then be used to develop new treatments or improve existing ones.

5) Reduces the need for human testing: Using animal disease models reduces the need for human testing, which can be time-consuming, expensive, and ethically challenging. However, it is important to note that animal models are not perfect substitutes for human subjects, and results obtained from animal studies may not always translate to humans.

6) They can be used to study infectious diseases: Animal disease models can be used to study infectious diseases such as HIV, TB, and malaria. These models allow researchers to understand how the disease is transmitted, how it progresses, and how it responds to treatment.

7) They can be used to study complex diseases: Animal disease models can be used to study complex diseases such as cancer, diabetes, and heart disease. These models allow researchers to understand the underlying mechanisms of the disease and test potential treatments.

8) They are cost-effective: Animal disease models are often less expensive than human clinical trials, making them a cost-effective way to conduct research.

9) They can be used to study drug delivery: Animal disease models can be used to study drug delivery and pharmacokinetics, which is important for developing new drugs and drug delivery systems.

10) They can be used to study aging: Animal disease models can be used to study the aging process and age-related diseases such as Alzheimer's and Parkinson's. This allows researchers to understand how aging contributes to disease and develop potential treatments.

There are several types of diabetes mellitus, including:

1. Type 1 DM: This is an autoimmune condition in which the body's immune system attacks and destroys the cells in the pancreas that produce insulin, resulting in a complete deficiency of insulin production. It typically develops in childhood or adolescence, and patients with this condition require lifelong insulin therapy.
2. Type 2 DM: This is the most common form of diabetes, accounting for around 90% of all cases. It is caused by a combination of insulin resistance (where the body's cells do not respond properly to insulin) and impaired insulin secretion. It is often associated with obesity, physical inactivity, and a diet high in sugar and unhealthy fats.
3. Gestational DM: This type of diabetes develops during pregnancy, usually in the second or third trimester. Hormonal changes and insulin resistance can cause blood sugar levels to rise, putting both the mother and baby at risk.
4. LADA (Latent Autoimmune Diabetes in Adults): This is a form of type 1 DM that develops in adults, typically after the age of 30. It shares features with both type 1 and type 2 DM.
5. MODY (Maturity-Onset Diabetes of the Young): This is a rare form of diabetes caused by genetic mutations that affect insulin production. It typically develops in young adulthood and can be managed with lifestyle changes and/or medication.

The symptoms of diabetes mellitus can vary depending on the severity of the condition, but may include:

1. Increased thirst and urination
2. Fatigue
3. Blurred vision
4. Cuts or bruises that are slow to heal
5. Tingling or numbness in hands and feet
6. Recurring skin, gum, or bladder infections
7. Flu-like symptoms such as weakness, dizziness, and stomach pain
8. Dark, velvety skin patches (acanthosis nigricans)
9. Yellowish color of the skin and eyes (jaundice)
10. Delayed healing of cuts and wounds

If left untreated, diabetes mellitus can lead to a range of complications, including:

1. Heart disease and stroke
2. Kidney damage and failure
3. Nerve damage (neuropathy)
4. Eye damage (retinopathy)
5. Foot damage (neuropathic ulcers)
6. Cognitive impairment and dementia
7. Increased risk of infections and other diseases, such as pneumonia, gum disease, and urinary tract infections.

It is important to note that not all individuals with diabetes will experience these complications, and that proper management of the condition can greatly reduce the risk of developing these complications.

The burden of chronic diseases is significant, with over 70% of deaths worldwide attributed to them, according to the World Health Organization (WHO). In addition to the physical and emotional toll they take on individuals and their families, chronic diseases also pose a significant economic burden, accounting for a large proportion of healthcare expenditure.

In this article, we will explore the definition and impact of chronic diseases, as well as strategies for managing and living with them. We will also discuss the importance of early detection and prevention, as well as the role of healthcare providers in addressing the needs of individuals with chronic diseases.

What is a Chronic Disease?

A chronic disease is a condition that lasts for an extended period of time, often affecting daily life and activities. Unlike acute diseases, which have a specific beginning and end, chronic diseases are long-term and persistent. Examples of chronic diseases include:

1. Diabetes
2. Heart disease
3. Arthritis
4. Asthma
5. Cancer
6. Chronic obstructive pulmonary disease (COPD)
7. Chronic kidney disease (CKD)
8. Hypertension
9. Osteoporosis
10. Stroke

Impact of Chronic Diseases

The burden of chronic diseases is significant, with over 70% of deaths worldwide attributed to them, according to the WHO. In addition to the physical and emotional toll they take on individuals and their families, chronic diseases also pose a significant economic burden, accounting for a large proportion of healthcare expenditure.

Chronic diseases can also have a significant impact on an individual's quality of life, limiting their ability to participate in activities they enjoy and affecting their relationships with family and friends. Moreover, the financial burden of chronic diseases can lead to poverty and reduce economic productivity, thus having a broader societal impact.

Addressing Chronic Diseases

Given the significant burden of chronic diseases, it is essential that we address them effectively. This requires a multi-faceted approach that includes:

1. Lifestyle modifications: Encouraging healthy behaviors such as regular physical activity, a balanced diet, and smoking cessation can help prevent and manage chronic diseases.
2. Early detection and diagnosis: Identifying risk factors and detecting diseases early can help prevent or delay their progression.
3. Medication management: Effective medication management is crucial for controlling symptoms and slowing disease progression.
4. Multi-disciplinary care: Collaboration between healthcare providers, patients, and families is essential for managing chronic diseases.
5. Health promotion and disease prevention: Educating individuals about the risks of chronic diseases and promoting healthy behaviors can help prevent their onset.
6. Addressing social determinants of health: Social determinants such as poverty, education, and employment can have a significant impact on health outcomes. Addressing these factors is essential for reducing health disparities and improving overall health.
7. Investing in healthcare infrastructure: Investing in healthcare infrastructure, technology, and research is necessary to improve disease detection, diagnosis, and treatment.
8. Encouraging policy change: Policy changes can help create supportive environments for healthy behaviors and reduce the burden of chronic diseases.
9. Increasing public awareness: Raising public awareness about the risks and consequences of chronic diseases can help individuals make informed decisions about their health.
10. Providing support for caregivers: Chronic diseases can have a significant impact on family members and caregivers, so providing them with support is essential for improving overall health outcomes.

Conclusion

Chronic diseases are a major public health burden that affect millions of people worldwide. Addressing these diseases requires a multi-faceted approach that includes lifestyle changes, addressing social determinants of health, investing in healthcare infrastructure, encouraging policy change, increasing public awareness, and providing support for caregivers. By taking a comprehensive approach to chronic disease prevention and management, we can improve the health and well-being of individuals and communities worldwide.

... and albuminuria category (A1, A2, A3). Causes of albuminuria can be discriminated between by the amount of protein excreted. ... Albuminuria is a pathological condition wherein the protein albumin is abnormally present in the urine. It is a type of ... The term albuminuria is now preferred in Nephrology since there is not a "small albumin" (microalbuminuria) or a "big albumin ... Also a urine dipstick test for proteinuria can give a rough estimate of albuminuria. This is because albumin is by far the ...
Orthostatic proteinuria (synonyms: orthostatic albuminuria, postural proteinuria) is a benign condition. A change in renal ...
Bell ME (September 1933). "Albuminuria in the normal male rat". The Journal of Physiology. 79 (2): 191-3. doi:10.1113/jphysiol. ... Comper WD, Hilliard LM, Nikolic-Paterson DJ, Russo LM (December 2008). "Disease-dependent mechanisms of albuminuria". American ...
Edelstein D, Brownlee M (January 1992). "Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats". Diabetologia. ... "Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin- ...
Dunhill, T. P.; Patterson, S. W. (1902). "Albuminuria following severe exercise in healthy persons". Intercolonial Medical ...
"The Bearing of Albuminuria on Life Assurance". British Medical Journal. 1 (1416): 348. doi:10.1136/bmj.1.1416.348. PMC 2197491 ...
Albuminuria release of the protein albumin in urine. As this protein is strongly conserved, this is evidence of abnormal kidney ...
... discovered albuminuria (about a half century before Richard Bright); one of the first scientists to identify urea in human ...
1855). "Cases of Albuminuria Occurring after Scarlatina, with Remarks". The Boston Medical and Surgical Journal. 53 (5): 92-99 ...
Lin, Julie; Fung, Teresa T.; Hu, Frank B.; Curhan, Gary C. (2011-02-01). "Association of dietary patterns with albuminuria and ... An albumin level above the upper limit values is called "macroalbuminuria", or sometimes just albuminuria. Sometimes, the upper ... "Associations of diet with albuminuria and kidney function decline". Clinical Journal of the American Society of Nephrology. 5 ( ... is now discouraged by Kidney Disease Improving Global Outcomes and has been replaced by moderately increased albuminuria. ...
Lin, Julie; Fung, Teresa T.; Hu, Frank B.; Curhan, Gary C. (2011-02-01). "Association of dietary patterns with albuminuria and ... Lin, Julie; Hu, Frank B.; Curhan, Gary C. (2010-05-01). "Associations of diet with albuminuria and kidney function decline". ...
It can be a risk factor for future albuminuria. In adults, the signs and symptoms of infection may still be present at the time ...
"Particulate Matter and Albuminuria, Glomerular Filtration Rate, and Incident CKD". Clinical Journal of the American Society of ... higher PM 2.5 exposure is associate with increased albuminuria. In women undergoing IVF treatment, increases in NO2 both at the ...
Dickinson, W. H. (1876). "The Croonian Lectures on the Pathology and Relations of Albuminuria". BMJ. 1 (799): 499-501. doi: ... The Pathology and Relations of Albuminuria 1875 Edward Headlam Greenhow, On Addison's Disease 1874 Charles Murchison, ...
He was the author of influential works associated with diabetes and albuminuria, and is credited with disproving the once-held ... Gansevoort, RT; Ritz, E (2008). "Hermann Senator and albuminuria--forgotten pioneering work in the 19th century". Nephrol Dial ... Berlin, A. Hirschwald, 1882, (Albuminuria in healthy and diseased states); translated into several foreign languages. Die ... "Hermann Senator and albuminuria--forgotten pioneering work in the 19th century". Nephrol Dial Transplant. 24 (3): 1058. doi: ...
Lucas RC (1833). "Form of late rickets associated with albuminuria, rickets of adolescents". The Lancet. 1 (3119): 993-994. doi ...
Crowley's family removed him from the school when he developed albuminuria. He then attended Malvern College and Tonbridge ...
The triad of protein leaking into the urine (proteinuria or albuminuria), rising blood pressure with hypertension and then ... Albumin measurements are defined as follows: Normal albuminuria: urinary albumin excretion ... on the measurement of abnormal levels of urinary albumin in a diabetic coupled with exclusion of other causes of albuminuria. ...
This leads to an elevated concentration of albumin in the urine (albuminuria). This albuminuria usually does not cause symptoms ...
Albuminuria has been used for initial diagnosis in children from as young as four years old but significant damage may have ... Also albuminuria, GFR, and lactic hydrogenase are used in determining CKD progression. The use of cystatin C may not be clear ... Specifically variants in G1 and G2 of apolipoprotein L1 in the African American have shown increased risk of albuminuria, and ... and worsening albuminuria. This is because sFLT-1 prevents the binding of vascular endothelial growth factor (VEGF) to a splice ...
He provided early descriptions of hematogenous albuminuria, uremic pericarditis and progressive polyserositis. The eponymous " ... Volume 15 Bamberger's albuminuria @ Who Named It JAMA: The Journal of the American Medical Association, Volume 25 Bamberger's ...
with J. F. Ward: Bury, Judsons.; Ward, J.F. (1 January 1910). "A case of postural albuminuria in a boy the subject of chorea". ...
Other clinical findings include albuminuria, hematuria, hepatic enzyme derangement, and cardiac arrhythmias. Doses as low as 10 ...
In people with type 2 diabetes, antihypertensive therapy with valsartan decreases the rate of progression of albuminuria ( ... "Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus". Journal of Hypertension. 25 (9): 1921-1926. doi: ...
Other clinical findings include albuminuria, hematuria, hepatic enzyme derangement, and cardiac arrhythmias. Doses as low as 10 ...
name="Cambridge 2017, p28-35." Donkin A S (1863) On the pathological relation between albuminuria and puerperal mania. ... one of those who first recognized the importance of albuminuria) in Edinburgh, and recognized that some cases of eclamptic ...
In men the significant predictors of CVD were diabetes, age, LDL, albuminuria, and hypertension. Unlike other ethnic groups, ... The significant independent predictors of CVD in Native American women were diabetes, age, obesity, LDL, albuminuria, ...
However, the trial did not reach the primary clinical endpoint of reduction in albuminuria. Following this, the company ...
In the European Union, finerenone is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) ... September 2015). "Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial". JAMA ...
A case of intermittent albuminuria and chromaturia]. Archiv für Pathologische Anatomie und Physiologie und für Klinische ...
Asian adults with diabetes and normal kidney function have a higher risk for albuminuria than non-Hispanic white adults, but ...
Albuminuria. Definition: The presence of albumin in the urine, an indicator of KIDNEY DISEASES. ... Synonyms (terms occurring on more labels are shown first): albuminuria More information: PubMed search and possibly Wikipedia ...
Albuminuria (too much protein in the urine). People with SCD often have albuminuria, or too much protein in the urine (possibly ...
Percentage of U.S. Veterans Receiving Albuminuria Testing Percentage of U.S. Veterans Receiving Albuminuria Testing The ... Albuminuria testing is higher among older Veterans except for those aged ≥70 years. More male than female Veterans received ... To view the frequency of albuminuria testing among U.S. Veterans by risk categories, select from the drop-down menu below. Risk ... 17.0%, 2019). Non-Hispanic White Veterans received slightly less albuminuria testing compared to other racial/ethnic groups ( ...
Albuminuria Testing in Hypertension and Diabetes: An Individual-Participant Data Meta-Analysis in a Global Consortium. ... Albuminuria Testing in Hypertension and Diabetes: An Individual-Participant Data Meta-Anal ...
Albuminuria. 27 (15.2). 1 (7.7). 3.7. Decreased renal function. 22 (12.4). 3 (23.1). 13.6. ...
Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet. 2009 Aug 15. 374(9689):543-50. [QxMD ... Albuminuria is seen in glomerular proteinuria. False-positive results can occur with recent exposure to iodinated radiocontrast ... Disease-dependent mechanisms of albuminuria. Am J Physiol Renal Physiol. 2008 Dec. 295 (6):F1589-600. [QxMD MEDLINE Link]. ... Cirillo M. Evaluation of glomerular filtration rate and of albuminuria/proteinuria. J Nephrol. 2010 Mar-Apr. 23(2):125-32. [ ...
Provigils official prescription information for Modafinil, given to patients and doctors.
ratio (UACR) albuminuria and. Background Cigarette smoking negatively affects kidney function. ratio (UACR) albuminuria and ... albuminuria (microalbuminuria vs. macroalbuminuria vs. normal) and CKD LY 344864 (yes/no) using multivariate GEE adjusting LY ... reveals significant associations of the nAChR gene family with kidney function variables including eGFR UACR and albuminuria ( ...
The urine protein dipstick test measures the presence of all proteins, including albumin, in a urine sample.
Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The ... Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The ... Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The ... Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals : The ...
We undertook a meta-analysis to assess the independent and combined associations of eGFR and albuminuria with mortality. ... Dive into the research topics of Association of estimated glomerular filtration rate and albuminuria with all-cause and ... We undertook a meta-analysis to assess the independent and combined associations of eGFR and albuminuria with mortality. ... We undertook a meta-analysis to assess the independent and combined associations of eGFR and albuminuria with mortality. ...
Association of single and joint metals with albuminuria and estimated glomerular filtration longitudinal change in middle-aged ... Albuminuria; Glomerular filtration rate; Metal mixtures; Kidney damage; Kidney function ...
The stages of albuminuria based on the UACR were determined as follows: normoalbuminuria, UACR , 30 mg/g Cr; microalbuminuria, ... Also, although this cross-sectional study was unable to clarify the causal relationship of the eGFR and albuminuria with ... The Association of Poor Psychological Status with Kidney Function, Albuminuria, and Quality of Life among DKD Patients. As ... The clinical outcomes included renal function, albuminuria, and the QOL in DKD patients. With these results, evidence was ...
Urogenital system - Frequent: albuminuria, urination impaired; Infrequent: amenorrhea,* cystitis, dysuria, hematuria, kidney ...
Albuminuria is most often caused by kidney damage from diabetes. But many other conditions can lead to kidney damage. These ... This is called albuminuria. If the amount of albumin is very small, but still abnormal, it is called microalbuminuria. ... Other conditions also cause albuminuria. These conditions include high blood pressure, heart failure, and cirrhosis. ...
Albuminuria. *Hemorrhage. *Vestibular impairment. *Gustatory disturbance. A patient with argyria must receive immediate medical ...
Persistent albuminuria, as measured by the urine albumin-creatinine ratio (ACR) in two urines from an individual, is used to ... Persistent albuminuria is used to determine kidney damage for categorizing persons as having stage 1 and stage 2 CKD. Two urine ... The comparison of estimates of the prevalence of albuminuria from the random and follow-up first-morning void urines may be of ... In NHANES III, a study of two random urines was used to estimate persistent albuminuria. ...
Albuminuria should be regarded as a surrogate for end stage renal disease. In our analyses of trials with baseline SBP less ... Thirdly, Emdin and colleagues showed a decreased risk of albuminuria, an outcome we did not analyse. The reviews differ on two ... Ace-Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects Study Group. Low-dose ramipril reduces ... already less than 140 mm Hg is associated with a reduced risk of stroke and albuminuria, and therefore challenged the ...
... effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. ...
Medscape - Indication-specific dosing for Arsobal (melarsoprol), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.
albuminuria). Rendes k r lm nyek k z tt a vizelet feh rj t nem tartalmaz, a hugyutak sz mos megbeteged se mellett azonban feh ... albuminuria). Rendes k r lm nyek k z tt a vizelet feh rj t nem tartalmaz, a hugyutak sz mos megbeteged se mellett azonban feh ...
Reduce the risk of certain complications in people who have diabetic nephropathy with albuminuria. For this use, Invokana is ... With albuminuria, you have high levels of a protein called albumin in your urine. ... With albuminuria, you have high levels of a protein called albumin in your urine. ... Reduce the risk of certain complications of diabetic nephropathy in people with albuminuria. Specifically, the drug lowers the ...
Albuminuria is most often caused by kidney damage from diabetes. But many other conditions can lead to kidney damage. These ... This is called albuminuria. If the amount of albumin is very small, but still abnormal, it is called microalbuminuria. ... Other conditions also cause albuminuria. These conditions include high blood pressure, heart failure, and cirrhosis. ...
Some individuals with low levels of albuminuria do not develop renal failure. In these persons, albuminuria may be due to the ... Mild albuminuria may be present if glycemia is not well regulated. Because of renal hyperfiltration, serum creatinine and urea ... In patients with albuminuria, blood pressure regulation is of critical importance in slowing the progression to renal failure. ... Diabetic nephropathy represents a distinct clinical syndrome characterized by albuminuria, hypertension, and progressive renal ...
Adiponectin regulates albuminuria and podocyte function in mice. The Journal of Clinical Investigation. 2008;. 118. (5):1645- ... but albuminuria, a marker of kidney damage, is related to adiponectin deficiency [172], further extending the protective ...
  • Sometimes albuminuria is also called proteinuria. (nih.gov)
  • Albuminuria is seen in glomerular proteinuria. (medscape.com)
  • In contrast a gene-family analysis considering the joint impact of all 61 SNPs reveals significant associations of the nAChR gene family with kidney function variables including eGFR UACR and albuminuria (all P's≤0.0001) after adjusting for established risk factors including cigarette smoking. (cancer8.info)
  • Single SNP analysis We first tested the association of each SNP with renal function variables including eGFR (continuous) UACR (continuous) albuminuria (microalbuminuria vs. macroalbuminuria vs. normal) and CKD LY 344864 (yes/no) using multivariate GEE adjusting LY 344864 for age sex study center BMI history of diabetes or hypertension or CVD smoking status (ever smoker vs. never) alcohol drinking (current vs. former vs. never) physical activity level and socioeconomic status. (cancer8.info)
  • Background: Substantial controversy surrounds the use of estimated glomerular filtration rate (eGFR) and albuminuria to define chronic kidney disease and assign its stages. (elsevierpure.com)
  • We undertook a meta-analysis to assess the independent and combined associations of eGFR and albuminuria with mortality. (elsevierpure.com)
  • Cox proportional hazards models were used to estimate hazard ratios (HRs) for all-cause and cardiovascular mortality associated with eGFR and albuminuria, adjusted for potential confounders. (elsevierpure.com)
  • Background - Data are limited with regard to the relations of low-grade albuminuria (below the microalbuminuria threshold) and incidence of cardiovascular disease (CVD) events in nondiabetic, nonhypertensive individuals. (elsevierpure.com)
  • To reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria ( 1 ). (nih.gov)
  • Reduce the risk of certain complications in people who have diabetic nephropathy with albuminuria. (medicalnewstoday.com)
  • For this use, Invokana is given to certain adults who have diabetic nephropathy (kidney damage that's caused by diabetes) with albuminuria* of greater than 300 milligrams per day. (medicalnewstoday.com)
  • ratio (UACR) albuminuria and chronic kidney disease (CKD). (cancer8.info)
  • 60 mL/minute/1.73 m2), and albuminuria (defined as UACR ≥ 30 mg/g). (nih.gov)
  • 60 ml/min/1.73 m² or albuminuria (urine albumin to creatinine ratio [UACR] ≥ 30 mg/g). (cdc.gov)
  • Albuminuria is defined as UACR ≥ 30 mg/g. (cdc.gov)
  • Albuminuria is a sign of kidney disease and means that you have too much albumin in your urine. (nih.gov)
  • With albuminuria, you have high levels of a protein called albumin in your urine. (medicalnewstoday.com)
  • We investigated the association between hypokalemia and the prevalence of albuminuria in a Japanese general population . (bvsalud.org)
  • We categorized them into four groups according to their concentration of serum potassium (sK) and performed a multivariate logistic regression analysis to determine the association between hypokalemia and the prevalence of albuminuria in this population . (bvsalud.org)
  • Compared to the subjects with sK = 4.1-4.5 mEq/L, the subjects with hypokalemia had a significantly high prevalence of albuminuria multivariable-adjusted odds ratio (OR) = 2.70 (95% confidence interval [CI] 1.84-3.96). (bvsalud.org)
  • Hypokalemia was significantly associated with the high prevalence of albuminuria in general population . (bvsalud.org)
  • Regardless of the presence/absence of renal dysfunction, hypertension , or hyperglycemia , hypokalemia was positively associated with the prevalence of albuminuria , and the associations were significant except for the subjects with renal dysfunction. (bvsalud.org)
  • 12. Prediction of coronary heart disease in a population with high prevalence of diabetes and albuminuria: the Strong Heart Study. (nih.gov)
  • Health care providers regularly test people for albuminuria as part of a routine medical exam and will closely monitor urine albumin in people with kidney disease. (nih.gov)
  • In a systematic review and meta-analysis, health eating patterns were associated with a 30% and 23% decreased incidence of chronic kidney disease and albuminuria. (renalandurologynews.com)
  • Adhering to a healthy diet may reduce the risk of chronic kidney disease (CKD) and albuminuria, according to a new systematic review and meta-analysis. (renalandurologynews.com)
  • Our findings suggest that TRPC6 promotes albuminuria, perhaps by promoting angiotensin II-dependent increases in Ca(2+), suggesting that TRPC6 blockade may be therapeutically beneficial in proteinuric kidney disease. (duke.edu)
  • People with SCD often have albuminuria, or too much protein in the urine (possibly an early sign of kidney disease). (cdc.gov)
  • Association of single and joint metals with albuminuria and estimated glomerular filtration longitudinal change in middle-aged adults from Spain: the Aragon workers health study. (cdc.gov)
  • BACKGROUND: The aim of this study was to examine the relationship of albuminuria to cardiovascular disease outcomes in diabetic patients undergoing treatment for stable coronary artery disease. (nih.gov)
  • Additionally, nonwhites with type-II diabetes and stable coronary artery disease who had mildly increased albuminuria had a Hazard ratio (HR) of 3.3 times (P = 0.028) for cardiovascular death, 3.1 times for (P = 0.002) all-cause mortality, and two times for (P = 0.015) MI during follow-up. (nih.gov)
  • CONCLUSIONS: Mildly increased albuminuria is a significant predictor of all-cause mortality in those with type-II diabetes mellitus and stable coronary artery disease, as well as for cardiovascular events those who are nonwhites. (nih.gov)
  • Increased albuminuria was also independently associated with cardiovascular disease risk. (nih.gov)
  • IMSEAR at SEARO: A cross sectional study of correlation between serum uric acid level and micro-albuminuria in Type 2 Diabetes Mellitus patients. (who.int)
  • Objectives: To study the association between serum uric acid and micro-albuminuria in patients with Type 2 Diabetes Mellitus. (who.int)
  • Hypokalemia was defined as having an sK = 3.1-3.5 mEq/L. After dividing the subjects into those with/without renal dysfunction, those with/without hypertension , and those with/without hyperglycemia , we examined the association between hypokalemia and albuminuria in each group. (bvsalud.org)
  • Veterans with hypertension were approximately 2.5 times more likely to receive albuminuria testing than those without hypertension. (cdc.gov)
  • You may also be able to protect your kidneys and reduce albuminuria by working with a registered dietitian who can help you plan meals and change your eating habits. (nih.gov)
  • The percentage of Veterans receiving albuminuria testing increased from 9.1% in 2005 to 21.9% in 2019. (cdc.gov)
  • More male than female Veterans received albuminuria testing (22.4% vs. 17.0%, 2019). (cdc.gov)
  • Conclusions: Higher Hba1c levels were associated positively with elevated serum uric acid and micro albuminuria. (who.int)
  • Page 64 odds of micro albuminuria were 1.02 times (95% CI 0.58 to 1.79, p value 0.944) in people with uric acid between 5 to 7.49 and 1.855times (95% CI 0.56 to 6.081, p value 0.30) in patients with uric acid level of 7.5 and above, as compared to people with uric acid levels below 5 mg/dl. (who.int)
  • Association between Hypokalemia and Albuminuria in a Japanese General Population. (bvsalud.org)
  • 9 12 Last year, a new systematic review was published, 13 concluding that treating people with a systolic blood pressure (SBP) already less than 140 mm Hg is associated with a reduced risk of stroke and albuminuria, and therefore challenged the relaxation of guidelines. (bmj.com)
  • Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence? (connectcost.eu)
  • Relationship of mildly increased albuminuria and coronary artery revascularization outcomes in patients with diabetes. (nih.gov)
  • Even though there is a weak positive correlation between the uric acid levels and micro albuminuria it was statistically not significant. (who.int)
  • 23%). The percentage of albuminuria testing is approximately five times higher for Veterans with diabetes than those without diabetes. (cdc.gov)
  • Albuminuria is an early manifestation of CKD. (bvsalud.org)
  • [ 8 ] In diabetic populations, physical activity is associated with lower albumin excretion, and it has led to regression of albuminuria in 5 of 6 subjects with baseline microalbuminuria in an interventional study. (medscape.com)
  • Albuminuria is a sign of kidney disease and means that you have too much albumin in your urine. (nih.gov)
  • Health care providers regularly test people for albuminuria as part of a routine medical exam and will closely monitor urine albumin in people with kidney disease. (nih.gov)
  • A health care provider often tests for albuminuria using a urine dipstick test followed by a urine albumin and creatinine measurement. (nih.gov)
  • Physical activity improves endothelial function so activity may reduce albuminuria. (medscape.com)
  • You may also be able to protect your kidneys and reduce albuminuria by working with a registered dietitian who can help you plan meals and change your eating habits. (nih.gov)
  • Despite the fact that albuminuria represents a key risk factor for chronic kidney disease (CKD), even in the absence of reduced filtration, testing for the condition is low among adult patients with diabetes and is even lower among those with hypertension , suggesting commonly missed opportunities for CKD detection and treatment, a new study shows. (medscape.com)
  • Among those with diabetes, albuminuria testing is consistently reported at 50% or less across a variety of settings, despite being recommended in most guidelines. (medscape.com)
  • 23%). The percentage of albuminuria testing is approximately five times higher for Veterans with diabetes than those without diabetes. (cdc.gov)
  • Relationship of mildly increased albuminuria and coronary artery revascularization outcomes in patients with diabetes. (nih.gov)
  • Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. (bvsalud.org)
  • DRI and ARB reduced albuminuria in hypertensive patients with type 2 diabetes . (bvsalud.org)
  • We compared the effect of aliskiren, a direct renin inhibitor (DRI), with that of angiotensin receptor blockers (ARBs) on albuminuria and urinary excretion of angiotensinogen , a marker of intrarenal renin-angiotensin system activity. (bvsalud.org)
  • Furthermore, while guidelines from the nonprofit organization Kidney Disease: Improving Global Outcomes (KDIGO) recommend staging CKD by both eGFR and albuminuria, the latter is often omitted. (medscape.com)
  • People with SCD often have albuminuria, or too much protein in the urine (possibly an early sign of kidney disease). (cdc.gov)
  • Persistent albuminuria is used to determine kidney damage for categorizing persons as having stage 1 and stage 2 CKD. (cdc.gov)
  • Two urine samples are needed to assess persistent albuminuria and confirm the presence of kidney damage. (cdc.gov)
  • [ 1 , 2 ] Since the underlying pathophysiology of albuminuria in HF is still debated, the present findings provide an intriguing explanation, linking albuminuria more to congestion than to an intrinsic renal disease ( Graphical Abstract ). (medscape.com)
  • Likewise, the available echo parameters showed that pulmonary pressures were higher in patients with albuminuria, along with a more prevalent dilated inferior vena cava. (medscape.com)
  • The authors also confirmed the independent prognostic value of albuminuria in predicting the risk of mortality and HF (re)hospitalization in HF patients with both reduced (HFrEF) and preserved ejection fraction (HFpEF). (medscape.com)
  • To investigate the extent of underdetection of albuminuria, researchers identified 192,108 patients in National Health and Nutrition Examination Surveys (NHANES) from 2007 to 2018. (medscape.com)
  • Overall, only 17.5% (33,629 patients) had undergone albuminuria testing. (medscape.com)
  • Among those patients, 34.3% had albuminuria, according to the model. (medscape.com)
  • Of those patients, only 5% underwent albuminuria testing, which detected only 10% of cases of albuminuria in this population. (medscape.com)
  • present exciting data about the role of albuminuria as a marker of systemic congestion in patients with HF. (medscape.com)
  • Patients with albuminuria were also on higher doses of loop diuretics, further evidence that clinical congestion was more advanced in these subjects. (medscape.com)
  • In the subgroup analysis , a significant reduction in the albuminuria was observed in the ARB group but not in the DRI group among high-normal albuminuria patients . (bvsalud.org)
  • In addition, ARB, but not DRI, reduced albuminuria even in patients with normal albuminuria . (bvsalud.org)
  • The authors explored the cross-sectional association between physical activity and albuminuria in 3,587 nondiabetic women in 2 US cohorts, the Nurses' Health Study I in 2000 and the Nurses' Health Study II in 1997. (medscape.com)
  • Because the overall association between physical activity and albuminuria may be clinically meaningful in nondiabetic populations, we examined this association in 3,587 participants in 2 US cohorts, the Nurses' Health Study (NHS) I in 2000 and the NHS II in 1997. (medscape.com)
  • Association of single and joint metals with albuminuria and estimated glomerular filtration longitudinal change in middle-aged adults from Spain: the Aragon workers health study. (cdc.gov)
  • Key reasons for the low rates of albuminuria testing could be that guidelines do not adequately emphasize such testing and that there is a lack of awareness of the need to take simple extra steps, first author Chi D. Chu, MD, of the Department of Medicine, University of California, San Francisco, told Medscape Medical News . (medscape.com)
  • The percentage of Veterans receiving albuminuria testing increased from 9.1% in 2005 to 21.9% in 2019. (cdc.gov)
  • More male than female Veterans received albuminuria testing (22.4% vs. 17.0%, 2019). (cdc.gov)
  • If there are similar effects of physical activity on the renal vasculature as there are on the cardiac vasculature, physical activity could protect against albuminuria. (medscape.com)